EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

RORγt inverse agonists demonstrating a margin between inhibition of IL-17A and thymocyte apoptosis

Mia Collins iD, Rikard Pehrson, Hanna Grindebacke, Agnes Leffler iD, Marie Ramnegård, Helena Rannikmäe, Nina Krutrök, Linda Yrlid, Charlotte Pollard, Ian Dainty, Frank Narjes, Stefan von Berg und 9 weitere

PLOS ONE · 16.01.2025 · 20 (1) · e0317090

DOI: 10.1371/journal.pone.0317090 ↗

Kurz gefasst

Fachartikel in der Zeitschrift PLOS ONE, online erschienen am 16.01.2025. Verfasst von Mia Collins und 20 weiteren Autor:innen. Beteiligte Einrichtung: Bioscience COPD/IPF, Research and Early Development, Respiratory & Immunology, BioPharmaceuticals R&D, AstraZeneca, Gothenburg, Sweden. Hauptthemen laut MEDLINE: Nuclear Receptor Subfamily 1, Group F, Member 3, Interleukin-17, Apoptosis, Thymocytes. Die Arbeit wurde bisher 5-mal zitiert (Crossref) und nennt 62 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Multiple genetic associations suggest a causative relationship between Th17-related genes coding for proteins, such as IL-17A, IL-23 and STAT3, and psoriasis. Further support for this link comes from the findings that neutralizing antibodies directed against IL-17A, IL-17RA and IL-23 are efficacious in diseases like psoriasis, psoriatic arthritis and ankylosing spondylitis. RORγt is a centrally positioned transcription factor driving Th17 polarization and cytokine secretion and modulation of RORγt may thus provide additional benefit to patients. However, RORγt also plays a role in the normal development of T cells in the thymus and genetic disruption of RORγt in the mouse leads to the development of lymphoma originating in the thymus. Whilst it is not established that down-regulation of RORγt activity would lead to the same consequence in humans, further understanding of the thymus effects is desirable to support progress of this target as a potential treatment of Th17-driven disease. Herein we present the characterisation of recently disclosed RORγt inverse agonists demonstrating target engagement and efficacy in vitro and in vivo against Th17 endpoints but requiring higher concentrations in vitro to affect thymocyte apoptosis.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Nuclear Receptor Subfamily 1, Group F, Member 3Interleukin-17ApoptosisThymocytesAnimalsHumansMiceTh17 CellsDrug Inverse Agonism

Substanzen

Nuclear Receptor Subfamily 1, Group F, Member 3Interleukin-17

Autor:innen und Institutionen

  • Bioscience COPD/IPF, Research and Early Development, Respiratory & Immunology, BioPharmaceuticals R&D, AstraZeneca, Gothenburg, Sweden.
  • Drug Metabolism and Pharmacokinetics, Research and Early Development, Respiratory & Immunology, BioPharmaceuticals R&D, AstraZeneca, Gothenburg, Sweden.
  • Medicinal Chemistry, Research and Early Development, Respiratory & Immunology, BioPharmaceuticals R&D, AstraZeneca, Gothenburg, Sweden.
  • Discovery Sciences, BioPharmaceuticals R&D, AstraZeneca, Gothenburg, Sweden.
  • Projects, Research and Early Development, Respiratory & Immunology, BioPharmaceuticals R&D, AstraZeneca, Gothenburg, Sweden.

ORCID-Profile: Mia Collins, Agnes Leffler, Antonio Llinas, Elisabeth Bäck

Zitieren

APA

Collins, M., Pehrson, R., Grindebacke, H., Leffler, A., Ramnegård, M., Rannikmäe, H., Krutrök, N., Yrlid, L., Pollard, C., Dainty, I., Narjes, F., von Berg, S., Llinas, A., Malmberg, A., McPheat, J., Hansson, E., Bäck, E., Bernström, J., Hansson, T. G., …, & Jirholt, J. (2025). RORγt inverse agonists demonstrating a margin between inhibition of IL-17A and thymocyte apoptosis. PLOS ONE, 20(1), e0317090. https://doi.org/10.1371/journal.pone.0317090

Vancouver

Collins M, Pehrson R, Grindebacke H, Leffler A, Ramnegård M, Rannikmäe H, et al. RORγt inverse agonists demonstrating a margin between inhibition of IL-17A and thymocyte apoptosis. PLOS ONE. 2025;20(1):e0317090. doi:10.1371/journal.pone.0317090

BibTeX
@article{Collins2025,
  author = {Collins, Mia and Pehrson, Rikard and Grindebacke, Hanna and Leffler, Agnes and Ramnegård, Marie and Rannikmäe, Helena and Krutrök, Nina and Yrlid, Linda and Pollard, Charlotte and Dainty, Ian and Narjes, Frank and von Berg, Stefan and Llinas, Antonio and Malmberg, Anna and McPheat, Jane and Hansson, Eva and Bäck, Elisabeth and Bernström, Jenny and Hansson, Thomas G and Keeling, David and Jirholt, Johan},
  title = {RORγt inverse agonists demonstrating a margin between inhibition of IL-17A and thymocyte apoptosis},
  journal = {PLOS ONE},
  year = {2025},
  volume = {20},
  number = {1},
  pages = {e0317090},
  doi = {10.1371/journal.pone.0317090}
}
Kostenlos starten →